Larson Richard A
Department of Medicine and the Cancer Research Center, University of Chicago, Chicago, IL 60637, USA.
Semin Hematol. 2006 Apr;43(2):126-33. doi: 10.1053/j.seminhematol.2006.01.007.
Although the median age for adults with acute lymphoblastic leukemia (ALL) is older than 60 years, relatively few of these patients have been enrolled on prospective clinical trials. The presence of coexisting medical disorders and unfavorable cytogenetic and biologic disease characteristics within this population presents considerable challenges for successful treatment using conventional chemotherapy programs. Selected patients have achieved remission and long-term survival following intensive chemotherapy. Philadelphia (Ph) chromosome (BCR/ABL)-positive ALL is particularly common among older patients. The availability of specific tyrosine kinase inhibitors is changing the prognosis for this challenging subset.
尽管成人急性淋巴细胞白血病（ALL）的中位年龄超过60岁，但这些患者中相对较少有人参加前瞻性临床试验。该人群中并存的内科疾病以及不利的细胞遗传学和生物学疾病特征，给使用传统化疗方案进行成功治疗带来了巨大挑战。部分患者在强化化疗后实现了缓解和长期生存。费城（Ph）染色体（BCR/ABL）阳性的ALL在老年患者中尤为常见。特异性酪氨酸激酶抑制剂的出现正在改变这一具有挑战性亚组的预后。
